Summit Therapeutics (SMMT)
(Real Time Quote from BATS)
$22.64 USD
-1.75 (-7.18%)
Updated Sep 23, 2024 10:24 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Summit Therapeutics PLC [SMMT]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
EGFR/MET Bispecific Agent Gets 1L EGFRmut NSCLC Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
WCLC Abstracts; China NMPA Grants Priority Review in 1L NSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
HARMONi-2 Data Preview Prior to WCLC Presidential Symposium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Reaching A Higher Summit in Oncology; Initiate at Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Phase 3 Ri-CoDIFy Did Not Meet Primary Endpoint; Maintain Neutral As Ridinilazole''s Future Remains Uncertain
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
3Q Recap; Ri-CoDIFy Top-line Data Readout On Target in 1Q22; Regulatory Path Remains Muddled; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Summit Jumps the Gun With Late Change to Primary Endpoint; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
2Q Recap: Two Ri-CoDIFy Phase 3 Trials Combine Into a Single Pivotal Trial With 753 Patients Enrolled
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
4Q20 Recap: Phase 3 Ri-CoDIFy Trials Enrollment Pace Rebounds; Maintain Neutral on Dilution Risk
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
We See a Financing Overhang as Phase 3 Trials Enroll Slower Than Anticipated; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
2Q Recap: Covid Weighs on Timeline; Enrollment in Pivotal Ri-CoDIFy Trials Slowing Further in 3Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
U.S. Redomiciliation Complete; Shares of SMMT Common Stock Begin Trading on the Nasdaq Today
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
We See Multiple Advantages in Summit''s U.S. Redomicile Plan; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Analysis of Phase 2 CoDIFy Data Highlights Ridinilazole''s Advantage Over Vancomycin; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Competitor Meets Primary Endpoint in Pivotal C. Diff Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
1Q20 Recap: Phase 3 Ri-CoDIFy Trials Continue Enrollment Amid COVID-19 Pandemic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
FY2019 Recap: Summit Made Several Key Hires As Ri-CoDIFy Continues Enrollment; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E